This inventor holds 5 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Turning Point Therapeutics, Inc., Qualcomm Incorporated. Active years: 2013-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2026
Title: Xin Zhang: Innovator in Macrocyclic Compounds
Introduction
Xin Zhang is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of macrocyclic compounds. With a total of 5 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Xin Zhang's latest patents include groundbreaking research on macrocyclic compounds that inhibit SRC and MET, as well as CSF1R. These compounds are designed to be used in pharmaceutical compositions aimed at treating cancer. His work not only highlights the potential of these compounds but also emphasizes their therapeutic applications in modern medicine.
Career Highlights
Throughout his career, Xin Zhang has worked with notable companies such as Turning Point Therapeutics, Inc. and Qualcomm Incorporated. His experience in these organizations has allowed him to refine his expertise and contribute to significant advancements in drug development.
Collaborations
Xin Zhang has collaborated with esteemed colleagues, including Jingrong Jean Cui and Evan W Rogers. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical field.
Conclusion
Xin Zhang's contributions to the development of macrocyclic compounds represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to impact the pharmaceutical industry positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile